2 not yet recruiting, 2 recruiting, 1 suspended. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Suspended 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Blinatumomab: new trials by email Literature Review of Blinatumomab trials Research Report on Blinatumomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Blinatumomab - Phase 2 Study, Blinatumomab | Phase 2 | Suspended | M.D. Anderson Cancer Center | 40 | 2026-04-21 | 2026-10-08 |
| Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Blinatumomab and Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia, Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2025-05-17 | 2026-03-24 |
| Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus Blinatumomab 9ug - Systemic Lupus Erythematosus (SLE), Children | Phase 1 | Recruiting | Mao Jianhua | 6 | 2024-12-08 | 2025-11-28 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lupus Erythematosus, Systemic (1)
Immune System Diseases (5) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Skin and Connective Tissue Diseases (1)
blinatumomab (5) · Inotuzumab Ozogamicin (1) · olverembatinib (1) · revumenib (1)
M.D. Anderson Cancer Center (3) · Mao Jianhua (1) · The First Affiliated Hospital of Soochow University (1)
United States (3) · China (2)
Elias J Jabbour, MD (2) · Elias Jabbour, MD (1) · Jianhua Mao, PhD, MD (1) · Sheng-Li Xue, M.D. (1)